 |
市場調査レポート
商品コード
1455079
嚢胞性線維症治療の世界市場規模、シェア、成長分析、薬剤クラス別、投与経路別-産業予測、2024～2031年Global Cystic Fibrosis Therapeutics Market Size, Share, Growth Analysis, By Drug Class(CFTR modulators, Mucolytics), By Route of Administration(Oral drugs and Inhaled drugs) - Industry Forecast 2024-2031 |
||||||
| 嚢胞性線維症治療の世界市場規模、シェア、成長分析、薬剤クラス別、投与経路別-産業予測、2024～2031年 |
|
出版日: 2024年03月16日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
嚢胞性線維症治療の世界市場規模は、2022年に約53億米ドルと評価され、2023年の60億2,000万米ドルから上昇し、予測期間（2023～2031年）のCAGRは13.50%で、2031年には165億7,000万米ドルに達すると予測されます。
嚢胞性線維症（CF）の有病率の上昇と治療率の向上は、予測期間を通じて嚢胞性線維症治療の需要を促進する主要理由の1つです。さらに、非営利団体が実施するプロジェクトの増加、公的・民間両方からの研究開発資金の増加、有利な償還政策の利用可能性などは、今後数年間の市場を形成すると予想される重要な要因のほんの一部に過ぎません。
患者数が年々増加していることから、効果的で経済的なCF治療の需要が高まっています。入手しやすい薬剤クラス別には、気管支拡大薬、粘液溶解薬、抗感染薬、抗生物質（経口、吸入、両親への栄養剤）、抗炎症薬、膵酵素サプリメントなどがあります。嚢胞性線維症膜貫通伝導調節因子（CFTR）調節剤もこ一覧に含まれています。
主要企業が開発中の薬剤組成物の数が増加していることは、市場拡大を促進すると予想される主要要因の1つです。さらに、市場の促進要因の1つは、現在の治療ポートフォリオを使用して対象顧客を広げるために実施されている研究の数が増加していることです。市場の拡大は、研究開発活動の活発化によって促進されると予想されます。
嚢胞性線維症治療市場の成長を促進すると思われるもう一つの重要な要因は、CF Worldwide、Cystic Fibrosis Organization、Cystic Fibrosis Canada、South African Cystic Fibrosis Confidence、South African Cystic Fibrosis Organizationなど、CF関連の活動に定期的に参加している数多くの慈善団体の存在です。これらの団体は、大手の研究開発活動を支援し、嚢胞性線維症の新しい治療法を発見するために多くの資金を費やしています。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
嚢胞性線維症治療の世界市場：薬剤クラス別
- 市場概要
- CF治療剤
- 粘液溶解薬
- 膵酵素サプリメント
- 気管支拡大薬
嚢胞性線維症治療の世界市場：投与経路別
- 市場概要
- 経口薬と吸入薬
嚢胞性線維症治療の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Vertex Pharmaceuticals Incorporated
- AbbVie Inc.
- Gilead Sciences, Inc.
- Genentech, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Perrigo Company plc
- Pharmaxis Ltd.
- Celtaxsys, Inc.
- Savara Inc.
- Kamada Ltd.
- Chiesi Farmaceutici S.p.A.
- Galapagos NV
- Proteostasis Therapeutics, Inc.
- Eloxx Pharmaceuticals, Inc.
- Insmed Incorporated
- Arcturus Therapeutics Holdings Inc.
- Translate Bio, Inc.
- Zogenix, Inc.
Global Cystic Fibrosis Therapeutics Market size was valued at around 5.30 billion in 2022 and is expected to rise from USD 6.02 billion in 2023 to reach a value of USD 16.57 Billion by 2031, at a CAGR of 13.50% over the forecast period (2023-2031).
The rising prevalence of cystic fibrosis (CF) along with an increasing treatment rate is one of the major reasons driving demand for cystic fibrosis treatments throughout the forecast period. In addition, more projects carried out by nonprofit organizations, more funding for research and development from both public and private sources, and the availability of advantageous reimbursement policies are just a few of the crucial factors anticipated to shape the market in the years to come.
The demand for effective and economical CF medicines rises as a result of an increase in patient growth year over year. A few easily accessible approved drug classes include bronchodilators, mucolytic medications, anti-infective, antibiotics (oral, inhaled, or parents feeding formulae), anti-inflammatory, and pancreatic enzyme supplements. Cystic fibrosis Transmembrane Conductivity Regulator (CFTR) modulators are also included in this list.
The rising number of drug compositions that the top players have in the works is one of the key factors anticipated to fuel market expansion. Moreover, one of the market's drivers is the increasing number of studies being carried out to broaden its target clientele using its current treatment portfolio. Market expansion is expected to be driven by increasing R&D activity.
Another significant factor that may be driving the growth of the cystic fibrosis therapeutics market is the existence of numerous charitable organizations that are regularly involved in CF-related activities, such as CF Worldwide, Cystic Fibrosis Organization, Cystic Fibrosis Canada, South African Cystic Fibrosis Confidence, and South African Cystic Fibrosis Organization. These groups are spending a lot of money to support the research and development efforts of major players and to discover new treatments for cystic fibrosis.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cystic Fibrosis Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cystic Fibrosis Therapeutics Market Segmental Analysis
The drug class, administration method, and geographic regions are the main factors that divide the worldwide market for cystic fibrosis therapies. The pancreatic enzyme supplements, CFTR modulators, mucolytics, and bronchodilators are the medication classes into which the market is divided. The market is divided into two categories based on the mode of administration: oral medications and inhaled drugs. The global market for cystic fibrosis treatments is divided into five regions: North America, Europe, Asia-Pacific, South America, and MEA.
Drivers of the Global Cystic Fibrosis Therapeutics Market
The market for cystic fibrosis treatments is primarily driven by the rising incidence of cystic fibrosis, a genetic condition affecting the reproductive, digestive, and respiratory systems. The need for cystic fibrosis therapies is fueled by the disease's irreversibility and lifetime treatment requirements.
Restraints in the Global Cystic Fibrosis Therapeutics Market
A significant obstacle to therapy availability for many people with cystic fibrosis is the high expense of available medicines, especially the more targeted ones. This has raised questions over these medications' cost and potential effects on healthcare systems.
Market Trends of the Global Cystic Fibrosis Therapeutics Market
Growing need for individualized therapy: As our knowledge of the genetic underpinnings of cystic fibrosis expands, so does the need for personalized medicine that specifically addresses the mutations that cause the illness. As more advanced treatments that target certain mutations are created, it is anticipated that this trend will continue in the years to come.
Use of combination medicines is rising: Combination medications, which address several mutations at once, are being used more frequently to treat cystic fibrosis. This is because treating many variants can improve outcomes, and many patients have multiple mutations contributing to their condition.
Growth in interest in creating treatments for non-classic mutations has been observed despite the majority of research in cystic fibrosis medications being concentrated on the most prevalent variants. Although certain mutations are less frequent, they can nevertheless contribute to the illness, and many people may benefit from treatments that specifically target them.
Growing emphasis on disease management: Despite the fact that there is currently no treatment for cystic fibrosis, patients' quality of life is being improved and disease management is receiving more attention. This involves creating treatments that specifically address the disease's symptoms as well as using nutritional and respiratory therapy to enhance general health and lung function.
Growing significance of patient advocacy: When it comes to the creation and acceptance of new cystic fibrosis treatments, patients and patient advocacy organizations are becoming more and more involved. This is partly because a lot of these therapies are pricey and might not be covered by insurance, which makes it hard for patients to get them on their own without assistance from organizations and advocacy groups.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Cystic Fibrosis Therapeutics Market by Drug Class
- Market Overview
- CFTR modulators
- Mucolytics
- Pancreatic enzyme supplements
- and Bronchodilators
Global Cystic Fibrosis Therapeutics Market by Route of Administration
- Market Overview
- Oral drugs and Inhaled drugs
Global Cystic Fibrosis Therapeutics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Vertex Pharmaceuticals Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Perrigo Company plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmaxis Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celtaxsys, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Savara Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kamada Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chiesi Farmaceutici S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Galapagos NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Proteostasis Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eloxx Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insmed Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arcturus Therapeutics Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Translate Bio, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zogenix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
